Skip to Content
Merck
  • Detection of initiating potential of non-genotoxic carcinogens in a two-stage hepatocarcinogenesis study in rats.

Detection of initiating potential of non-genotoxic carcinogens in a two-stage hepatocarcinogenesis study in rats.

The Journal of toxicological sciences (2014-09-23)
Ko Omura, Takeki Uehara, Yuji Morikawa, Hitomi Hayashi, Kunitoshi Mitsumori, Keiichi Minami, Masayuki Kanki, Hiroshi Yamada, Atsushi Ono, Tetsuro Urushidani
ABSTRACT

We previously reported a toxicogenomics-based prediction model for hepatocarcinogens in which the expression patterns of signature genes following repeated doses of either genotoxic or non genotoxic compounds were similar. Based on the results of our prediction model, we hypothesized that repeated doses of non-genotoxic carcinogens might have initiating potential. Here, we conducted a two stage hepatocarcinogenesis study in rats exposed to the initiating agent nitrosodiethylamine (DEN), and hepatotoxic compounds thioacetamide (TAA), methapyrilene (MP) and acetaminophen (APAP) for 1-2 weeks followed by the liver tumor promoter phenobarbital (PB). The duration of initial treatment was determined based on positive results from our prediction model. Combined treatment of 3 or 30 mg/kg of genotoxic DEN and PB induced marked increases in altered hepatocellular foci and a DEN dose-dependent increase in the number and area of glutathione S-transferase-placental form (GST-P)-positive foci. A low number of altered hepatocellular foci were also observed in rats treated with TAA at a dose of 45 mg/kg.MP at a dose of 100 mg/kg induced a very low number of foci, but APAP did not. Hierarchical clustering analysis using gene expression data revealed that 2-week treatment with TAA at a dose of 30 mg/kg and MP at 45 mg/kg induced specific expression of DNA damage-related genes, similar to 1-week treatment with DEN at a dose of 30 mg/kg. These results suggest that TAA and MP induce DNA damage, which partially supports our hypothesis. Although this study does not indicate whether tumor growth in response to these compounds can be assessed in this model, our results suggest that cumulative treatment with non genotoxic TAA might have initiating potential in the liver.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
N-Nitrosodiethylamine, liquid
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
N-Nitrosodiethylamine, ISOPAC®
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Acetaminophen, BioXtra, ≥99.0%
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Acetaminophen, meets USP testing specifications, 98.0-102.0%, powder
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Acetaminophen, analytical standard
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
N-Nitrosodiethylamine, ≥99.0% (GC)
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Thioacetamide, reagent grade, 98%
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Thioacetamide, ACS reagent, ≥99.0%
SKU
Pack Size
Availability
Price
Quantity
Supelco
N-Nitrosodiethylamine, analytical standard
SKU
Pack Size
Availability
Price
Quantity
Supelco
Acetaminophen solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
SKU
Pack Size
Availability
Price
Quantity
Supelco
Acetaminophen, Pharmaceutical Secondary Standard; Certified Reference Material
SKU
Pack Size
Availability
Price
Quantity
USP
Acetaminophen, United States Pharmacopeia (USP) Reference Standard
SKU
Pack Size
Availability
Price
Quantity
Paracetamol, European Pharmacopoeia (EP) Reference Standard
SKU
Pack Size
Availability
Price
Quantity